Tag #Stem Cell Therapy

Showing 1 to 6 of 6 results

theguardian.com

🌐 85% Global Worthiness

Aug 21, 16:20

UK Companies Mislead Parents with Unproven Tooth Stem Cell Treatments

Three UK companies are misleading parents by marketing tooth stem cell banking as a treatment for diabetes and autism, costing approximately £1,900, despite expert claims of a lack of supporting evidence, raising ethical concerns.

UK Companies Mislead Parents with Unproven Tooth Stem Cell Treatments

Three UK companies are misleading parents by marketing tooth stem cell banking as a treatment for diabetes and autism, costing approximately £1,900, despite expert claims of a lack of supporting evidence, raising ethical concerns.

Progress

52% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What regulatory measures are needed to prevent the exploitation of parental anxieties concerning children's health through the marketing of medically unproven procedures?

The long-term impact of this practice could involve parents incurring significant financial costs for a medically ineffective procedure, potentially diverting resources from evidence-based treatments. The lack of regulation and oversight allows companies to exploit parental anxieties, emphasizing the need for stricter controls on the marketing of unproven medical interventions. This case underscores the importance of clear, evidence-based communication in healthcare.

smh.com.au

🌐 85% Global Worthiness

Jul 25, 07:14

NeuroScientific Appoints CMO, Share Price Soars 371%

NeuroScientific Biopharmaceuticals appointed Dr. Catherine Cole as its chief medical officer, boosting its share price by 371 percent since June and accelerating development of its StemSmart stem cell technology for treating severe immune complications; interim results from a Crohn's disease trial a...

NeuroScientific Appoints CMO, Share Price Soars 371%

NeuroScientific Biopharmaceuticals appointed Dr. Catherine Cole as its chief medical officer, boosting its share price by 371 percent since June and accelerating development of its StemSmart stem cell technology for treating severe immune complications; interim results from a Crohn's disease trial a...

Progress

56% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does Dr. Cole's background and experience contribute to NeuroScientific's development and regulatory pathway for its StemSmart technology?

Dr. Cole's extensive experience in pediatric hematology and oncology, coupled with her leadership roles in stem cell transplantation, will significantly contribute to NeuroScientific's growth. Her expertise will be crucial in navigating regulatory approvals for StemSmart in Australia and internationally. The StemSmart technology, using mesenchymal stromal stem cells (MSCs), shows promise in treating various immune-mediated disorders, offering a potential solution for patients with limited treatment options.

elpais.com

🌐 90% Global Worthiness

Jan 29, 22:11

Lab-Grown Heart Patch Shows Successful Human Heart Regeneration

A 46-year-old woman with severe heart failure received a lab-grown heart patch containing 800 million umbilical cord cells; post-transplant analysis confirmed successful heart regeneration, offering hope for millions with heart failure.

Lab-Grown Heart Patch Shows Successful Human Heart Regeneration

A 46-year-old woman with severe heart failure received a lab-grown heart patch containing 800 million umbilical cord cells; post-transplant analysis confirmed successful heart regeneration, offering hope for millions with heart failure.

Progress

52% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does this experimental heart patch compare to other attempts at heart regeneration, and what are the limitations and challenges that still need to be addressed?

This research, published in Nature, demonstrates that lab-grown heart patches can integrate into human heart tissue, offering hope for the 99% of advanced heart failure patients ineligible for transplants. The patch, derived from umbilical cord cells, significantly improved one patient's cardiac output from 10% to 35%.

smh.com.au

🌐 85% Global Worthiness

Jul 28, 10:12

NeuroScientific Bolsters Leadership Team for StemSmart Commercialization

NeuroScientific Biopharmaceuticals appointed Nathan Smith as CEO and Catherine Cole as chief medical officer, bolstering its team as it prepares for the commercial launch of its StemSmart stem cell technology, acquired through a $4.1 million purchase of Isopgen in June, which treats critically ill p...

NeuroScientific Bolsters Leadership Team for StemSmart Commercialization

NeuroScientific Biopharmaceuticals appointed Nathan Smith as CEO and Catherine Cole as chief medical officer, bolstering its team as it prepares for the commercial launch of its StemSmart stem cell technology, acquired through a $4.1 million purchase of Isopgen in June, which treats critically ill p...

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How did NeuroScientific Biopharmaceuticals acquire the StemSmart technology, and what is its therapeutic application?

NSB's recent appointments signal its commitment to advancing StemSmart's commercialization. Smith's expertise in navigating regulatory pathways and scaling cell therapies, combined with Cole's medical expertise, positions NSB to capitalize on StemSmart's potential. The company's share price has risen significantly since June, reflecting investor confidence.

npr.org

🌐 85% Global Worthiness

Apr 17, 16:15

Stem-Cell Transplants Show Promise in Parkinson's Treatment

Two small studies revealed stem-cell transplants significantly eased Parkinson's symptoms in patients, with one showing a 20-point improvement on a standard scale; the FDA approved one treatment for a final-stage trial before potential approval, offering hope for the 1 million Americans with this di...

Stem-Cell Transplants Show Promise in Parkinson's Treatment

Two small studies revealed stem-cell transplants significantly eased Parkinson's symptoms in patients, with one showing a 20-point improvement on a standard scale; the FDA approved one treatment for a final-stage trial before potential approval, offering hope for the 1 million Americans with this di...

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What were the key scientific and technological hurdles overcome to achieve these stem-cell transplantation results?

Stem-cell transplants, derived from either human embryonic stem cells or induced pluripotent stem cells, produced dopamine and alleviated symptoms. Success follows decades of research, overcoming challenges in producing the right type of dopamine-producing neurons and scaling up cell production for clinical use. This marks a potential breakthrough after previous fetal tissue transplants yielded mixed results.

welt.de

🌐 85% Global Worthiness

Jan 29, 19:11

Cardiac Patch Improves Heart Function in First Human Trial

A clinical trial in Germany shows that a cardiac patch containing 400 million heart cells improved a patient's heart function by 4% in three months, paving the way for a potential long-term treatment for heart failure.

Cardiac Patch Improves Heart Function in First Human Trial

A clinical trial in Germany shows that a cardiac patch containing 400 million heart cells improved a patient's heart function by 4% in three months, paving the way for a potential long-term treatment for heart failure.

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the immediate, measurable effects of the cardiac patch implant on heart function in the first human trial?

A new cardiac patch, containing 400 million heart cells, improved the left ventricle's pumping capacity from 35% to 39% in a 46-year-old woman with advanced heart failure over three months. The patch, tested successfully in rats and rhesus monkeys, is now being used in a clinical trial involving 15 patients, with plans to treat 53.

Showing 1 to 6 of 6 results